Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a valuable tool for identifying trends and new threats. As part of its programme for developing and improving drug supply indicators, the EMCDDA has been expanding its monitoring to include measures of wider drug-related crime, including DRH. However, there appears to be a significant gap in the available European data on this topic.
An EMCDDA Paper released today provides an overview of the information available on drug-related homicide (DRH) in Europe. This first snapshot provides practitioners and policymakers with the current state of the art on this topic.
EMCDDA Director Alexis Goosdeel will today address the 38th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) taking place on 23 and 24 May in Bucharest. A key theme on the congress programme is the emergence of new psychoactive substances (NPS).
What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA, present the evidence on active case finding as a key measure to diagnose communicable diseases early. The two agencies advise to actively offer testing for hepatitis B, hepatitis C and HIV to all people in prison and to conduct universal testing for tuberculosis at prison entry.
What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA present evidence on active case finding as a key measure to diagnose communicable diseases early. The publication is launched in the first Spring European Hepatitis-HIV Testing Week (18–25 May 2018).
What is the impact of cannabis use on driving? Do edible and smoked cannabis products affect drivers in the same way? These are among the questions addressed in a new policy briefing on cannabis and driving, published today.
With cannabis use and policy evolving internationally, drug-impaired driving has become an increasingly relevant policy issue. This briefing aims to provide those concerned with policy developments in the field of cannabis with a brief overview of current knowledge and the latest developments in the area of driving.
EMCDDA Director Alexis Goosdeel will address a conference hosted by the Lithuanian Drug, Tobacco and Alcohol Control Department (NTAKD) in Vilnius today, as the organisation prepares to present a new strategy (2018–2028) to the Lithuanian parliament and government.
Dedicated to Lithuania’s drug policy review, with its human rights and health approach, the conference will underline the importance of a balanced and long-term drug policy, geared towards the creation of a healthy and safe society.
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.
This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.
Today the European Union has decided to subject two new synthetic cannabinoids to control measures across the 28 Member States. The substances in question are ADB-CHMINACA and CUMYL-4CN-BINACA, which have been raising health concerns in Europe.
The European Drug Report 2018: Trends and Developments will be launched on 7 June in Brussels. Accompanying the report will be the 2018 Statistical Bulletin, and 30 Country Drug Reports, presenting summaries of national drug phenomena in the EU-28, Turkey and Norway.
Darknet markets — also known as cryptomarkets — provide a largely anonymous platform for trading in a range of illicit goods and services. It is estimated that around two thirds of the offers on darknet markets are drug-related. Drug sales on these markets, although modest when compared to the overall retail drug market, are significant and appear to be expanding. EU-based suppliers are important players in the darknet ecosystem, the evolution of which is shown in this timeline.
For more than 20 years, the European information network on drugs and drug addiction (Reitox), has been the cornerstone of the European drug monitoring and reporting system, to which it contributes by collecting, analysing, interpreting and disseminating data at national level, as well as by defining the tools for monitoring. The EMCDDA 2025 strategy, endorsed in 2016, aims at contributing to a healthier and more secure Europe. In this context, Reitox is currently defining the new strategic goals for the network as a whole and how these will be operationalised and achieved.
Drugs and drug-related harms continue to challenge prison systems in Europe and interventions in this setting must be driven by evidence gathered through monitoring, data-collection and research. The remarks come in conclusions published by the World Health Organization Regional Office for Europe (WHO–Europe), in collaboration with Public Health England and the EMCDDA.
Today cannabis is sold openly in 573 ‘coffeeshops’ operating in 103 of the 380 municipalities in the Netherlands.
Facilitating evidence-based health decision-making among professionals, patients and policymakers will be just one of the issues discussed today by EMCDDA Director Alexis Goosdeel and Chief Executive Officer of the Cochrane Collaboration Mark Wilson.
A call for abstracts is now open for the 9th annual conference of the European Society for Prevention Research (EUSPR).
The Justice and Home Affairs Council has adopted today Council conclusions on alternatives to coercive sanctions for drug using offenders.
Together, we the Heads of EU agencies and Joint undertakings commit to zero tolerance towards sexual harassment and we cannot and will not accept harassment of any form in our agencies.
The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EU drugs agency (EMCDDA).
The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in around 60 European cities and towns (hereinafter referred to as ‘cities’) to explore the drug-taking habits of those who live in them. The results provide a valuable snapshot of the drug flow through the cities involved, revealing marked geographical variations*.
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 19 December 2017.
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 19 December 2017.
EMCDDA Director Alexis Goosdeel is in Switzerland today for a two-day meeting with representatives of the Federal Office of Public Health (FOPH).
The United Nations Commission on Narcotic Drugs (CND), the central UN policy-making body on drug-related matters, holds its 61st session in Vienna from 12–18 March 2018.
The Central Asian Drug Action Programme (CADAP), is currently in its sixth phase and reflects the EU’s long-term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction.
Environmental prevention policies and interventions seek to limit opportunities for unhealthy or risky behaviour or promote the availability of healthier options in order to prevent problems associated with substance use. They do so by altering the environment in ways that can unconsciously influence behaviour, thus complementing more established approaches that seek to build knowledge and skills.
In a new report published today, Environmental substance use prevention interventions in Europe, the EMCDDA offers a first operational definition of the concept and an initial overview of where and how such interventions are being used in the region.
Today, EMCDDA Director Alexis Goosdeel is in Brussels for an exchange of views with the European Parliament’s Committee for Environment, Public Health and Food Safety (ENVI).